ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3
Greatest benefits were observed in those with endocrine sensitive disease and those who had not received prior chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.